New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

摘要: The cyclooxygenase (COX)-2-selective nonsteroidal anti-inflammatory drugs (NSAIDs; coxibs) were developed in order to reduce upper gastrointestinal (GI) side effects associated with traditional nonselective NSAIDs. This article presents an overview of clinical trials showing the efficacy coxibs for treatment patients arthritis. In osteoarthritis trials, more effective than placebo and similarly compared standard doses Some studies lasted up a year showed effectiveness long-term osteoarthritis. There are currently few adequately powered comparing 2 first-generation coxibs, celecoxib rofecoxib. Of head-to-head agents, 1 indicated similar efficacy, whereas other superiority rofecoxib at dose 25 mg daily 200 daily. enrolling rheumatoid arthritis, also have shown superior that no different endoscopic studies, GI safety tolerability profile has been consistently large outcome least rofecoxib, significantly reduced risk confirmed complicated events conventional NSAID naproxen. Both NSAIDs naproxen ibuprofen arthritis not taking low-dose aspirin. Therefore, provide relief pain from is comparable NSAIDs, but lower incidence complications.